News & Events

AIMEDICS Chairman, Mr Martin Greenberg announced today the company has secured new funding of $2.04 million.  Mr Greenberg said these funds were provided by GBS Venture Partners’ Federal Government backed IIFF investment fund and a founding investor.

CEO of AIMEDICS, Mr Victor Skladnev said this funding would be applied to the commercialisation of the HypoMon® product.  The HypoMon® is an overnight, non-invasive, hypoglycaemia (low blood glucose) monitor and alarm for people with insulin dependent diabetes.

Mr Skladnev said hypoglycaemia is a major health concern for those living with insulin requiring diabetes.  The HypoMon® can provide many of these people with a safer night’s sleep.

GBS Venture Partners is a leading healthcare venture capital firm based in Australia.

For further information contact AIMEDICS CEO Victor Skladnev ph+61 2 92094514 

Website:  www.aimedics.com